ZA201206055B - Antibodies against cxcr4 - Google Patents
Antibodies against cxcr4Info
- Publication number
- ZA201206055B ZA201206055B ZA2012/06055A ZA201206055A ZA201206055B ZA 201206055 B ZA201206055 B ZA 201206055B ZA 2012/06055 A ZA2012/06055 A ZA 2012/06055A ZA 201206055 A ZA201206055 A ZA 201206055A ZA 201206055 B ZA201206055 B ZA 201206055B
- Authority
- ZA
- South Africa
- Prior art keywords
- antibodies against
- against cxcr4
- cxcr4
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30306010P | 2010-02-10 | 2010-02-10 | |
| GBGB1002238.2A GB201002238D0 (en) | 2010-02-10 | 2010-02-10 | Antibodies |
| PCT/GB2011/000175 WO2011098762A2 (en) | 2010-02-10 | 2011-02-10 | Antibodies against cxcr4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201206055B true ZA201206055B (en) | 2014-01-29 |
Family
ID=42110504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2012/06055A ZA201206055B (en) | 2010-02-10 | 2012-08-13 | Antibodies against cxcr4 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8748107B2 (https=) |
| EP (1) | EP2534177A2 (https=) |
| JP (2) | JP6045914B2 (https=) |
| KR (1) | KR20120130767A (https=) |
| CN (1) | CN103003306B (https=) |
| AU (1) | AU2011214179B2 (https=) |
| BR (1) | BR112012020173A2 (https=) |
| CA (1) | CA2788400A1 (https=) |
| CO (1) | CO6630117A2 (https=) |
| EA (1) | EA201290759A1 (https=) |
| GB (1) | GB201002238D0 (https=) |
| MX (1) | MX2012009144A (https=) |
| NZ (1) | NZ601943A (https=) |
| SG (1) | SG182795A1 (https=) |
| WO (1) | WO2011098762A2 (https=) |
| ZA (1) | ZA201206055B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2723380B1 (en) | 2011-06-24 | 2019-08-21 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| IN2015DN00140A (https=) * | 2012-08-31 | 2015-06-12 | Argen X Bv | |
| EP3125919A4 (en) * | 2014-02-19 | 2018-01-03 | Microconstants China Inc. | Chemokine receptor antagonist and its combinational therapy |
| US10647766B2 (en) * | 2014-12-17 | 2020-05-12 | Cancer Research Technology Limited | Anti-CXCL12 antibody molecules and their uses |
| IL256665B2 (en) * | 2015-07-23 | 2023-10-01 | Boehringer Ingelheim Int | IL-23A Targeting Compound and B-Cell Activating Factor Nucleic Acids Encoding Them and Use of Products Containing Them |
| EP3408378B1 (en) | 2016-01-25 | 2022-01-12 | NantCell, Inc. | Nk cells with altered cxcl12/cxcr4 signaling |
| EP3417653B1 (en) * | 2016-02-15 | 2021-08-25 | Corning Optical Communications LLC | Methods for centralized channel selection across different cells in a radio access network |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US20210275589A1 (en) | 2018-07-13 | 2021-09-09 | Nanjing Legend Biotech Co. Ltd. | Co-receptor systems for treating infectious diseases |
| AU2021205893A1 (en) | 2020-01-08 | 2022-06-23 | Synthis Therapeutics, Inc. | ALK5 inhibitor conjugates and uses thereof |
| EP4347643A4 (en) * | 2021-05-27 | 2025-09-17 | Us Gov Veterans Affairs | HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO STREPTOLYSIN O AND METHODS OF USE |
| WO2024127456A1 (ja) | 2022-12-12 | 2024-06-20 | 日本たばこ産業株式会社 | たばこシート、たばこシートを製造する方法、たばこ充填物、及び喫煙物品 |
| CN117003876B (zh) * | 2023-08-31 | 2024-06-18 | 恺佧生物科技(上海)有限公司 | 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| WO1990010457A1 (en) | 1989-03-14 | 1990-09-20 | New York University | Method of treating hiv infections using immunotoxins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| EP1306095A3 (en) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| DE19801265C1 (de) | 1998-01-15 | 1999-08-12 | Deutsches Krebsforsch | Inhibierung von CD95-unabhängiger Apoptose bei AIDS |
| US6863887B1 (en) | 1998-03-30 | 2005-03-08 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
| US6610834B1 (en) | 1998-11-18 | 2003-08-26 | Peter I. Lobo | Human IgM antibodies to chemokine receptors |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| EP1179541B1 (en) | 1999-04-28 | 2004-06-16 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| US7005503B2 (en) | 2002-02-08 | 2006-02-28 | Genetastix Corporation | Human monoclonal antibody against coreceptors for human immunodeficiency virus |
| WO2003066830A2 (en) | 2002-02-08 | 2003-08-14 | Genetastix Corporation | Human monoclonal antibodies against membrane proteins |
| DE10240064A1 (de) | 2002-08-30 | 2004-03-11 | Universitätsklinikum Freiburg | CXCR4-Rezeptor-Antagonisten |
| US20050266009A1 (en) | 2003-06-30 | 2005-12-01 | Savient Pharmaceuticals, Inc. | Antibodies and uses thereof |
| US7776564B2 (en) * | 2004-04-30 | 2010-08-17 | Five Prime Therapeutics, Inc. | Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use |
| WO2006089141A2 (en) | 2005-02-18 | 2006-08-24 | Dana-Farber Cancer Institute | Antibodies against cxcr4 and methods of use thereof |
| KR101722261B1 (ko) * | 2006-10-02 | 2017-04-03 | 메다렉스, 엘.엘.시. | Ｃｘｃｒ4에 결합하는 인간 항체 및 이의 용도 |
| FR2915102B1 (fr) | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
| EA201071300A1 (ru) | 2008-05-14 | 2011-06-30 | Эли Лилли Энд Компани | Антитела к cxcr4 |
-
2010
- 2010-02-10 GB GBGB1002238.2A patent/GB201002238D0/en not_active Ceased
-
2011
- 2011-02-10 EP EP11730035A patent/EP2534177A2/en not_active Withdrawn
- 2011-02-10 MX MX2012009144A patent/MX2012009144A/es not_active Application Discontinuation
- 2011-02-10 CA CA2788400A patent/CA2788400A1/en not_active Abandoned
- 2011-02-10 BR BR112012020173A patent/BR112012020173A2/pt not_active IP Right Cessation
- 2011-02-10 JP JP2012552459A patent/JP6045914B2/ja not_active Expired - Fee Related
- 2011-02-10 SG SG2012056321A patent/SG182795A1/en unknown
- 2011-02-10 AU AU2011214179A patent/AU2011214179B2/en not_active Ceased
- 2011-02-10 WO PCT/GB2011/000175 patent/WO2011098762A2/en not_active Ceased
- 2011-02-10 EA EA201290759A patent/EA201290759A1/ru unknown
- 2011-02-10 NZ NZ601943A patent/NZ601943A/en not_active IP Right Cessation
- 2011-02-10 US US13/024,698 patent/US8748107B2/en not_active Expired - Fee Related
- 2011-02-10 CN CN201180019263.1A patent/CN103003306B/zh not_active Expired - Fee Related
- 2011-02-10 KR KR1020127023204A patent/KR20120130767A/ko not_active Ceased
-
2012
- 2012-08-13 ZA ZA2012/06055A patent/ZA201206055B/en unknown
- 2012-09-03 CO CO12150358A patent/CO6630117A2/es unknown
-
2014
- 2014-05-16 US US14/279,728 patent/US9353185B2/en not_active Expired - Fee Related
-
2016
- 2016-05-11 US US15/152,414 patent/US20160244527A1/en not_active Abandoned
- 2016-07-29 JP JP2016149925A patent/JP2017012179A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN103003306A (zh) | 2013-03-27 |
| GB201002238D0 (en) | 2010-03-31 |
| MX2012009144A (es) | 2012-10-01 |
| JP2017012179A (ja) | 2017-01-19 |
| WO2011098762A8 (en) | 2011-10-20 |
| JP6045914B2 (ja) | 2016-12-14 |
| WO2011098762A3 (en) | 2012-01-19 |
| CN103003306B (zh) | 2016-09-07 |
| US20110311449A1 (en) | 2011-12-22 |
| WO2011098762A2 (en) | 2011-08-18 |
| BR112012020173A2 (pt) | 2019-09-24 |
| EA201290759A1 (ru) | 2013-03-29 |
| US9353185B2 (en) | 2016-05-31 |
| JP2013519367A (ja) | 2013-05-30 |
| US8748107B2 (en) | 2014-06-10 |
| CA2788400A1 (en) | 2011-08-18 |
| CO6630117A2 (es) | 2013-03-01 |
| EP2534177A2 (en) | 2012-12-19 |
| US20160244527A1 (en) | 2016-08-25 |
| AU2011214179A1 (en) | 2012-09-13 |
| KR20120130767A (ko) | 2012-12-03 |
| AU2011214179B2 (en) | 2015-08-06 |
| US20140369925A1 (en) | 2014-12-18 |
| NZ601943A (en) | 2014-11-28 |
| SG182795A1 (en) | 2012-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272831B (en) | Meditops and Meditop binding antibodies and their use | |
| IL259436A (en) | Antibodies against 3angptl and their uses | |
| ZA201209004B (en) | Anti-fgfr2 antibodies | |
| GB201000467D0 (en) | Antibodies | |
| PT2581113T (pt) | Anticorpo anti-tim-3 | |
| LT2530091T (lt) | Anti-dll3 antikūnas | |
| IL221371A0 (en) | Anti-lrp6 antibodies | |
| PL2616489T3 (pl) | Przeciwciało anty-huTNFR1 | |
| ZA201302459B (en) | Antibodies | |
| IL232399A0 (en) | Anti-2fgfr antibodies and their use | |
| ZA201206055B (en) | Antibodies against cxcr4 | |
| PT2946791T (pt) | Anticorpos anti-cd277 e suas utilizações | |
| IL225667A0 (en) | A new antigen | |
| GB201020738D0 (en) | Antibodies | |
| PT2603528T (pt) | Anticorpos glicosilados em fab | |
| GB201007957D0 (en) | Antibody | |
| GB201005062D0 (en) | Antibodies | |
| GB201020751D0 (en) | Antibodies | |
| GB201017780D0 (en) | Antibody | |
| IL226635B (en) | Human anti-sod1 antibodies | |
| AU331238S (en) | Seating | |
| AU331237S (en) | Seating | |
| PL2528476T3 (pl) | Mebel do siedzenia |